What is the 13F Pro Quality Score for LXRX?

13F Pro ranks LEXICON PHARMACEUTICALS, INC. (LXRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LXRX's current score at https://13fpro.ai/research/LXRX (free sign-up required for the full ranking).

Which hedge funds own the most LXRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LXRX include Artal Group S.A., FMR, Siren, L.L.C.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LXRX as soon as new 13F filings post.

Where does 13F Pro source LXRX data?

All LEXICON PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. LEXICON PHARMACEUTICALS, INC. files with the SEC under CIK 1062822. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LXRX in?

LEXICON PHARMACEUTICALS, INC. (LXRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LXRX research updated on 13F Pro?

LXRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LEXICON PHARMACEUTICALS, INC.(LXRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1062822 LXRX stock profile & AI dashboard →

13F Pro Quality Score

33.1/100

Rank #2,239 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

99.7/100

Profitability

10.6/100

Balance Sheet

11.9/100

Earnings Quality

30.0/100

Free Cash Flow

6.9/100

Institutional Flow

85.9/100

Revenue Scale

13.5/100

Dilution Risk

7.4/100

LXRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LEXICON PHARMACEUTICALS, INC. (LXRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LXRX at 33.1/100 on a 32-signal composite quality model, placing it at rank #2,239 of 2,879 stocks — the bottom half of the AI-ranked universe. LXRX scores in the top quartile across revenue growth (99.7), institutional flow (85.9). Areas of concern include free cash flow (6.9) and profitability (10.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LEXICON PHARMACEUTICALS, INC. reports quarterly revenue of $21.1M, net income of $-1.0M, free cash flow of $-14.7M. Top institutional holders of LXRX by reported 13-F value include Artal Group S.A., FMR, Siren, L.L.C., based on the most recent SEC filings. LXRX trades on the Nasdaq exchange and files with the SEC under CIK 1062822. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LXRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEXICON PHARMACEUTICALS, INC. directly from SEC EDGAR. LEXICON PHARMACEUTICALS, INC.'s 13F Pro composite quality score has ranged between 6 and 40 since 2021, currently 33.1 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

✦

Fun facts about LEXICON PHARMACEUTICALS, INC.

Quirks, history, and lore behind LXRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
Annual revenue in the low hundreds of millions, driven almost entirely by one approved drug — a tough way to run a business, but not unusual in specialty pharma.
3
The History
Founded in the late 1990s, it spent decades building a proprietary gene knockout mouse platform to systematically identify drug targets — a genuinely unusual research strategy for a small biotech.
4
The Secret
Its signature technology, the OmniBank knockout mouse library, let scientists knock out virtually every gene in the mouse genome to figure out what each one actually does in disease.
5
The Lore
After years of pipeline heartbreak, the company finally landed an approved drug for a rare heart condition — ATTR cardiomyopathy — putting it in competition with much larger players in a suddenly hot disease area.
6
The Giveaway
Its approved drug sotagliflozin (also used in heart failure) and its ticker LXRX are the breadcrumbs — a Woodlands, Texas biotech that bet its whole existence on mouse genetics paying off.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$21.1M

Net Income

Q1 2026

$-1.0M

Free Cash Flow

Q1 2026

$-14.7M

D/E Ratio

Q1 2026

0.24

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+22260.4% YoY

$31.1MFY 2024

FY20 $24.0MFY21 $298.0KFY22 $139.0KFY24 $31.1M

Net Income

-96.6% YoY

$-200.4MFY 2024

FY20 $-58.6MFY21 $-87.8MFY22 $-101.9MFY24 $-200.4M

Operating Income

-95.6% YoY

$-197.1MFY 2024

FY20 $-47.8MFY21 $-87.1MFY22 $-100.8MFY24 $-197.1M

EPS (Diluted)

-1.6% YoY

$-0.63FY 2024

FY20 $-0.53FY21 $-0.60FY22 $-0.62FY24 $-0.63

Total Assets

+53.6% YoY

$298.4MFY 2024

FY20 $203.8MFY21 $136.9MFY22 $194.3MFY24 $298.4M

Total Debt

+106.4% YoY

$100.3MFY 2024

FY20 $12.3MFY21 $1.2MFY22 $48.6MFY24 $100.3M

Op. Cash Flow

-101.2% YoY

$-178.8MFY 2024

FY20 $-143.0MFY21 $-87.0MFY22 $-88.9MFY24 $-178.8M

Metric	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$31.1M +22260.4%	$139.0K -53.4%	$298.0K -98.8%	$24.0M -92.5%	$322.1M +409.5%	$63.2M
Net Income	$-200.4M -96.6%	$-101.9M -16.2%	$-87.8M -49.8%	$-58.6M -145.0%	$130.1M +208.0%	$-120.5M
Operating Income	$-197.1M -95.6%	$-100.8M -15.7%	$-87.1M -82.2%	$-47.8M -133.8%	$141.4M +237.0%	$-103.3M
EPS (Diluted)	$-0.63 -1.6%	$-0.62 -3.3%	$-0.60 -13.2%	$-0.53 -145.7%	$1.16 +201.8%	$-1.14
Total Assets	$298.4M +53.6%	$194.3M +41.9%	$136.9M -32.8%	$203.8M -51.2%	$417.7M +47.0%	$284.1M
Total Debt	$100.3M +106.4%	$48.6M +3950.0%	$1.2M -90.2%	$12.3M -95.3%	$259.6M +3.4%	$251.0M
Operating Cash Flow	$-178.8M -101.2%	$-88.9M -2.1%	$-87.0M +39.1%	$-143.0M -225.6%	$113.8M +176.6%	$-148.6M

AI Insight: LXRX Financial Trends

Debt cut nearly in half since Q1 2025 and equity surged to $203M in Q1 2026, but sustained profitability remains elusive with revenue still lumpy.

• Total debt declined from $101M in Q1 2025 to $50M in Q1 2026, a 50% reduction over four quarters.

• Equity rebounded sharply to $203M in Q1 2026 after falling steadily from $240M in Q2 2024 to $108M in Q4 2025.

• Revenue remains highly volatile, swinging from $1M in Q1 2025 to $29M in Q2 2025 and back to $5M in Q4 2025, suggesting no recurring base.

• The lone profitable quarter was Q2 2025 ($3M net income, $17M op CF); every other quarter in the table shows losses.

⚠ Operating cash flow remains negative at -$15M in Q1 2026 despite near-breakeven net income — cash burn persists.

⚠ Revenue spiked to $21M in Q1 2026 from $5M in Q4 2025; confirm whether this reflects durable product sales or one-time payments.

⚠ Equity jump to $203M in Q1 2026 from $108M likely reflects a capital raise — dilution impact warrants scrutiny.

AI Insight: LXRX Ratio Trends

LXRX's profitability remains deeply negative on a TTM basis despite Q1 2026 showing the least-bad quarterly losses in over a year.

• D/E ratio fell sharply from 0.82 in Q1 2025 to 0.24 in Q1 2026, indicating meaningful deleveraging over four quarters.

• Operating margin improved from -123.3% in Q4 2024 to -4.7% in Q1 2026, but remains negative and volatile quarter-to-quarter.

• Q2 2025 was the sole quarter with positive metrics — OpMargin 12.9%, ROE 10.1% — surrounded by deep losses, suggesting a one-off event.

• TTM ROE of -12.9% and ROIC of -9.6% confirm sustained capital destruction on a trailing twelve-month basis.

⚠ Q3 2025 OpMargin collapsed to -85.9% after a positive Q2 2025; extreme quarter-to-quarter swings signal highly unstable earnings quality.

⚠ D/E dropped from 0.82 to 0.24 — monitor whether this reflects debt paydown or equity dilution, which would pressure existing shareholders.

⚠ Q1 2026 ROIC of -1.6% is the least negative in the dataset; watch whether this nascent improvement is sustained in Q2 2026.

Get alerted when LXRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LEXICON PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LXRX

Artal Group S.A.
$241.4M154,734,327 sh
FMR LLC
$70.3M45,056,338 sh
Siren, L.L.C.
$69.1M44,303,518 sh
Sessa Capital IM, L.P.
$27.9M17,912,961 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.8M9,519,167 sh
Point72 Asset Management, L.P.
$12.2M7,814,606 sh
MILLENNIUM MANAGEMENT LLC
$7.7M4,944,731 sh
BlackRock, Inc.
$5.2M3,322,219 sh
GEODE CAPITAL MANAGEMENT, LLC
$4.9M3,169,111 sh
JANE STREET GROUP, LLC
$4.2M2,665,938 sh

Fund	Value	Shares
Artal Group S.A.	$241.4M	154,734,327
FMR LLC	$70.3M	45,056,338
Siren, L.L.C.	$69.1M	44,303,518
Sessa Capital IM, L.P.	$27.9M	17,912,961
VANGUARD CAPITAL MANAGEMENT LLC	$14.8M	9,519,167
Point72 Asset Management, L.P.	$12.2M	7,814,606
MILLENNIUM MANAGEMENT LLC	$7.7M	4,944,731
BlackRock, Inc.	$5.2M	3,322,219
GEODE CAPITAL MANAGEMENT, LLC	$4.9M	3,169,111
JANE STREET GROUP, LLC	$4.2M	2,665,938

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LXRX on your watchlist

Track score changes the day LEXICON PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LXRX a good stock to buy?

13F Pro's AI-powered analysis of LEXICON PHARMACEUTICALS, INC. (LXRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LXRX are available on the LXRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LXRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LXRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LEXICON PHARMACEUTICALS, INC.'s investment landscape.